Ahn, Jin Seok; Ahn, Yong Chan; Kim, Joo-Hang; Lee, Chang Geol; Cho, Eun Kyung; Lee, Kyu Chan; Chen, Ming; Kim, Dong-Wan; Kim, Hoon-Kyo; Min, Young Joo; Kang, Jin-Hyoung; Choi, Jin-Hyuck; Kim, Sang-We; Zhu, Guangying; Wu, Yi-Long; Kim, Sung Rok; Lee, Kyung Hee; Song, Hong Suk; Choi, Yoon-La; Sun, Jong-Mu; Jung, Sin-Ho; Ahn, Myung-Ju; Park, Keunchil
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2015Aug ; 33 ( 24 ) :2660-6.
PMID : 26150444
ÀúÀÚ »ó¼¼Á¤º¸
Ahn, Jin Seok -
Ahn, Yong Chan -
Kim, Joo-Hang -
Lee, Chang Geol -
Cho, Eun Kyung -
Lee, Kyu Chan -
Chen, Ming -
Kim, Dong-Wan -
Kim, Hoon-Kyo -
Min, Young Joo -
Kang, Jin-Hyoung -
Choi, Jin-Hyuck -
Kim, Sang-We -
Zhu, Guangying -
Wu, Yi-Long -
Kim, Sung Rok -
Lee, Kyung Hee -
Song, Hong Suk -
Choi, Yoon-La -
Sun, Jong-Mu -
Jung, Sin-Ho -
Ahn, Myung-Ju -
Park, Keunchil -
ABSTRACT
PURPOSE: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced non-small-cell lung cancer (LA-NSCLC). PATIENT AND
METHODS: Patients were randomly assigned to either CCRT alone (observation arm) or CCRT followed by CC (consolidation arm). CCRT with docetaxel (20 mg/m(2)) and cisplatin (20 mg/m(2)) was administered every week for 6 weeks with a total dose of 66 Gy of thoracic radiotherapy in 33 fractions. In the consolidation arm, patients were further treated with three cycles of DP (35 mg/m(2) each on days 1 and 8, every 3 weeks). The primary end point was 40% improvement in progression-free survival (PFS) compared with observation.
RESULTS: From October 2005 to April 2011, 437 patients were randomly assigned. Seventeen patients did not start CCRT as a result of consent withdrawal or ineligibility reasons after random assignment, leaving 420 patients for this analysis (n = 211 for observation; n = 209 for consolidation). Patient characteristics were similar in both arms. In the consolidation arm, 143 patients (68%) received CC, of whom 88 (62%) completed three planned cycles. The median PFS was 8.1 months in the observation arm and 9.1 months in the consolidation arm (hazard ratio, 0.91; 95% CI, 0.73 to 1.12; P = .36). Median overall survival times were 20.6 and 21.8 months in the observation and consolidation arms, respectively (HR, 0.91; 95% CI, 0.72 to 1.25; P = .44). CONCLUSION: CC with DP after CCRT with weekly DP in LA-NSCLC failed to further prolong PFS. CCRT alone should remain the standard of care. CI - ??2015 by American Society of Clinical Oncology.
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/radiotherapy; Chemoradiotherapy; Cisplatin/administration & dosage; Female; Humans; Lung Neoplasms/*drug therapy/pathology/radiotherapy; Male; Middle Aged; Neoplasm Staging; Taxoids/administration & dosage
MESH
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/radiotherapy, Chemoradiotherapy, Cisplatin/administration & dosage, Female, Humans, Lung Neoplasms/*drug therapy/pathology/radiotherapy, Male, Middle Aged, Neoplasm Staging, Taxoids/administration & dosage
¸µÅ©